Objective: Primary Sjögren’s Syndrome (pSS) causes significant systemic symptoms including fatigue as well as glandular dysfunction. There are currently no effective systemic therapies; however, open label series have suggested that rituximab may be beneficial for systemic and glandular manifestations. Therefore, we performed a double blind, placebo controlled, randomised pilot study of the efficacy of rituximab in reducing fatigue in pSS.
Methods: 17 patients with pSS and a score on fatigue visual analogue scale (VAS) >50 were randomised to receive either 2 infusions of rituximab 1g or placebo; patients also received oral and intravenous steroids. Outcome measures included: the proportion of patients with >20% reduction in fatigue VAS, changes in pSS related symptoms, health related quality of life and immunological parameters of pSS. These were measured 6 months after therapy.
Results: There was significant improvement from baseline in fatigue VAS in the rituximab group (p<0.001) in contrast to the placebo group (p=0.147). There was a significant difference between the groups at 6 months in the social functioning score of SF-36 (p=0.01) and a trend to significant difference in the mental health domain score of SF-36 (p=0.06). There was one episode of serum sickness in the rituximab treated group.
Conclusions: This is the first double blind study of rituximab in pSS to show benefit; further studies are justified.
- Sjögren's syndrome